| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Anne E Kiltie | Q39896443 |
| P2093 | author name string | F C Hamdy | |
| M Kerr | |||
| N L Sharma | |||
| B Groselj | |||
| P2860 | cites work | HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination | Q24670026 |
| Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor | Q28474504 | ||
| Epigenetics in cancer | Q29617139 | ||
| Modulation of radiation response by histone deacetylase inhibition | Q33214371 | ||
| Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery | Q82996604 | ||
| Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer | Q33392099 | ||
| HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy | Q33778769 | ||
| HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells | Q34062580 | ||
| Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. | Q34093052 | ||
| Mre11-Rad50-Nbs1 conformations and the control of sensing, signaling, and effector responses at DNA double-strand breaks | Q34432615 | ||
| Targeting abnormal DNA double strand break repair in cancer | Q34457557 | ||
| Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. | Q34488424 | ||
| Histone deacetylases 9 and 10 are required for homologous recombination | Q34624058 | ||
| Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy | Q34915905 | ||
| Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic | Q35038016 | ||
| Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy | Q35975127 | ||
| Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo | Q37244481 | ||
| Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? | Q37252722 | ||
| The role of histone deacetylases (HDACs) in human cancer | Q37453782 | ||
| The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax | Q37805244 | ||
| Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography | Q38022419 | ||
| The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers | Q38095611 | ||
| Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. | Q38327984 | ||
| Adamantanyl-histone deacetylase inhibitor H6CAHA exhibits favorable pharmacokinetics and augments prostate cancer radiation sensitivity | Q39601063 | ||
| Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining | Q39662092 | ||
| Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition | Q39677848 | ||
| Scriptaid, a novel histone deacetylase inhibitor, enhances the response of human tumor cells to radiation | Q39767757 | ||
| Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells | Q39875544 | ||
| Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. | Q39978688 | ||
| Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer | Q40200801 | ||
| Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci | Q40240295 | ||
| Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity | Q40401113 | ||
| Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study | Q43105772 | ||
| Influence of valproic acid on outcome of high-grade gliomas in children. | Q46408823 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported | Q15643954 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | DNA repair | Q210538 |
| neoplasm | Q1216998 | ||
| radiosensitizer | Q2126468 | ||
| histone deacetylase inhibitors | Q3569101 | ||
| DNA damage | Q5205747 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 748-754 | |
| P577 | publication date | 2013-01-29 | |
| 2013-03-05 | |||
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair | |
| P478 | volume | 108 |
| Q42702942 | A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma |
| Q91642406 | A three layered histone epigenetics in breast cancer metastasis |
| Q64099911 | Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70 |
| Q98564346 | Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation |
| Q35108007 | Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy |
| Q53681442 | Bromodomain proteins: repairing DNA damage within chromatin. |
| Q38187679 | Cancer biomarker discovery: current status and future perspectives. |
| Q48596058 | Chemotherapy is getting 'smarter'. |
| Q41592921 | Chromatin remodeling modulates radiosensitivity of the daughter cells derived from cell population exposed to low- and high-LET irradiation |
| Q33907067 | Chromatin-regulating proteins as targets for cancer therapy |
| Q41872120 | Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage |
| Q52590685 | Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi. |
| Q31133958 | Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells. |
| Q55359395 | Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. |
| Q91588484 | Comparison of Radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in Pancreatic Cancer Cells |
| Q48308220 | Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors. |
| Q35176178 | DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: an outcome-predicting and treatment-implicating study |
| Q36038071 | Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair |
| Q36553263 | Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer |
| Q42873813 | Effect of trichostatin a on SGC-7901 gastric cancer cells |
| Q37658507 | Effects of Valproic Acid on Radiation-Induced Chromosomal Aberrations in Human Lymphocytes |
| Q92405274 | Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells |
| Q38970754 | Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus |
| Q92259153 | Focus-ING on DNA Integrity: Implication of ING Proteins in Cell Cycle Regulation and DNA Repair Modulation |
| Q92626235 | Folate-mediated and pH-responsive chidamide-bound micelles encapsulating photosensitizers for tumor-targeting photodynamic therapy |
| Q50317222 | HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130. |
| Q37388728 | Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro |
| Q37223734 | Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin |
| Q34109472 | Histones: Controlling Tumor Signaling Circuitry |
| Q38817005 | How do tumor cells respond to HDAC inhibition? |
| Q36946725 | Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia |
| Q38748006 | Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition |
| Q60028152 | Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis |
| Q99238268 | Improving the Efficacy of Tumor Radiosensitization Through Combined Molecular Targeting |
| Q33584050 | Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy |
| Q64061318 | Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy |
| Q64065358 | Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [F]TFAHA |
| Q40084337 | Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways |
| Q34474232 | Oxidative stress diverts tRNA synthetase to nucleus for protection against DNA damage |
| Q37676851 | Proteomics insights into DNA damage response and translating this knowledge to clinical strategies |
| Q39035998 | Radiation-induced alterations of histone post-translational modification levels in lymphoblastoid cell lines |
| Q38761174 | Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity? |
| Q47908872 | Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity |
| Q39112866 | Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression. |
| Q35209439 | Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays |
| Q41874822 | Rapid and transient protein acetylation changes in response to DNA damage |
| Q38989816 | Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide |
| Q35018496 | Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. |
| Q46038047 | Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. |
| Q34413200 | Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors |
| Q27023204 | Targeting DNA damage response in cancer therapy |
| Q50649482 | Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. |
| Q35821728 | Targeting Histone Deacetylases in Diseases: Where Are We? |
| Q50926267 | Targeting histone deacetylase 4/ubiquitin-conjugating enzyme 9 impairs DNA repair for radiosensitization of hepatocellular carcinoma cells in mice. |
| Q33755207 | The Effect of VPA on Increasing Radiosensitivity in Osteosarcoma Cells and Primary-Culture Cells from Chemical Carcinogen-Induced Breast Cancer in Rats |
| Q51746838 | The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma. |
| Q47987478 | The influence of ketogenic therapy on the 5 R's of radiobiology. |
| Q38877902 | The molecular hallmarks of epigenetic control |
| Q39249171 | The rs7003908 (T>G) polymorphism in the XRCC7 gene and the risk of cancers |
| Q41347312 | Time dependent modulation of tumor radiosensitivity by a pan HDAC inhibitor: abexinostat. |
| Q47429195 | Trek1 contributes to maintaining nasal epithelial barrier integrity |
| Q46265462 | Valproic Acid Sensitizes Hepatocellular Carcinoma Cells to Proton Therapy by Suppressing NRF2 Activation |
| Q64389971 | Valproic acid causes radiosensitivity of breast cancer cells disrupting the DNA repair pathway |
| Q36544286 | Valproic acid enhances the efficacy of radiation therapy by protecting normal hippocampal neurons and sensitizing malignant glioblastoma cells |
| Q38826037 | Valproic acid modulates radiation-enhanced matrix metalloproteinase activity and invasion of breast cancer cells. |
Search more.